Emergex Vaccines is a clinical stage, privately-held, biotechnology company headquartered in Abingdon in the UK, and focused on addressing some of the world’s most immediate health threats, including viral diseases such as Dengue Fever, Zika, Ebola and pandemic Flu, as well as serious intra-cellular bacterial infections.

Emergex is developing a pipeline of innovative CD8+ T-Cell Adaptive Vaccines that have the potential to deliver fast, broad and long lasting immunity to reduce serious illness associated with infectious diseases.

Emergex’s vaccines are entirely synthetic, which means that they do not require biological steps to be manufactured, and in turn do not introduce live viruses, RNA or DNA into people. An added benefit is that synthetic vaccines can be stored at ambient temperature, avoiding the need for refrigeration or freezing and making vaccination much more convenient all around the world. Our T-Cell vaccine candidates have also been designed to be delivered trans-dermally, avoiding the need for traditional needles and intra-muscular injections.

Drawing on a rich scientific heritage and extensive international research, Emergex has developed collaborations in the US, EU, Singapore and Brazil with leading vaccine research bodies, including George Mason University in the US, the Institute of Molecular and Cell Biology (IMCB) of Singapore, and Brazil-based Bio-Manguinhos/Fiocruz in Brazil, and George Mason University in the US